New diabetes pill enters first human safety tests

NCT ID NCT05579314

Completed Disease control Sponsor: Sciwind Biosciences USA Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests an experimental oral drug called XW014 in healthy volunteers and people with type 2 diabetes. The main goal is to check safety and how the body handles the drug. 127 participants will receive either the drug or a placebo in single or multiple doses. This is a first-in-human study, so it's too early to know if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XW014 (oral tablet or capsule)
What this could lead to: If successful, this could lead to a new oral medication for type 2 diabetes that helps control blood sugar.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

ICON - Early Development Services

Lenexa, Kansas, 66219, United States
ICON - Early Development Services

San Antonio, Texas, 78209, United States
ICON - Early Development Services

Salt Lake City, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.